On May 13, 2022, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Mounjaro (tirzepatide), a once-weekly injection for the treatment of type 2 diabetes mellitus (T2DM). Pathophysiology of Type 2 Diabetes Mellitus Incretins are the...